Literature DB >> 17429047

Polycystic kidney disease.

Peter Igarashi1, Stefan Somlo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17429047     DOI： 10.1681/ASN.2007030299

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  23 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

Review 2.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

3.  Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts.

Authors:  Lucy X Fan; Xia Zhou; William E Sweeney; Darren P Wallace; Ellis D Avner; Jared J Grantham; Xiaogang Li
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

4.  Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Authors:  James J Beaudoin; Jacqueline Bezençon; Yanguang Cao; Katsuhiko Mizuno; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2018-11-30       Impact factor: 3.922

5.  Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD.

Authors:  Ao Li; Yuchen Xu; Song Fan; Jialin Meng; Xufeng Shen; Qian Xiao; Yuan Li; Li Zhang; Xiansheng Zhang; Guanqing Wu; Chaozhao Liang; Dianqing Wu
Journal:  JCI Insight       Date:  2018-03-08

6.  Loss of Bicc1 impairs tubulomorphogenesis of cultured IMCD cells by disrupting E-cadherin-based cell-cell adhesion.

Authors:  Yulong Fu; Ingyu Kim; Peiwen Lian; Ao Li; Liang Zhou; Cunxi Li; Dan Liang; Robert J Coffey; Jie Ma; Ping Zhao; Qimin Zhan; Guanqing Wu
Journal:  Eur J Cell Biol       Date:  2010-03-09       Impact factor: 4.492

7.  Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.

Authors:  Shan Qin; Mary Taglienti; Surya M Nauli; Leah Contrino; Ayumi Takakura; Jing Zhou; Jordan A Kreidberg
Journal:  J Clin Invest       Date:  2010-09-13       Impact factor: 14.808

8.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Authors:  Ronak Lakhia; Matanel Yheskel; Andrea Flaten; Ezekiel B Quittner-Strom; William L Holland; Vishal Patel
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-13

9.  Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease.

Authors:  William J Brock; James J Beaudoin; Jason R Slizgi; Mingming Su; Wei Jia; Sharin E Roth; Kim L R Brouwer
Journal:  Int J Toxicol       Date:  2018 Mar/Apr       Impact factor: 2.032

10.  Polycystic kidney disease in the medaka (Oryzias latipes) pc mutant caused by a mutation in the Gli-Similar3 (glis3) gene.

Authors:  Hisashi Hashimoto; Rieko Miyamoto; Naoki Watanabe; Dai Shiba; Kenjiro Ozato; Chikako Inoue; Yuko Kubo; Akihiko Koga; Tomoko Jindo; Takanori Narita; Kiyoshi Naruse; Kazuko Ohishi; Keiko Nogata; Tadasu Shin-I; Shuichi Asakawa; Nobuyoshi Shimizu; Tomotsune Miyamoto; Toshio Mochizuki; Takahiko Yokoyama; Hiroshi Hori; Hiroyuki Takeda; Yuji Kohara; Yuko Wakamatsu
Journal:  PLoS One       Date:  2009-07-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.